Sheela Rao, MBBS, MD, FRCP, is a consultant medical oncologist specializing in gastrointestinal cancers and cancers of unknown primary within the gastrointestinal unit at the Royal Marsden Hospital.
Retifanlimab Approval Sets New Standard of Care in Advanced Anal Cancer: Sheela Rao, MBBS, MD, FRCP
With the FDA approval of retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, researchers are now focusing on resistance mechanisms and future therapies, according to Sheela Rao, MBBS, MD, FRCP, of The Royal Marsden Hospital.